Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024BMJOpen Access

5PSQ-038 Real-world safety of ibrutinib in clinical practice in patients with chronic lymphocytic leukaemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MRM Valera RubioJCJ Cordero-RamosLDL Moñino Domínguez

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rubio et al. (2024) studied this question.

synapsesocial.com/papers/68e76a16b6db6435876df2eehttps://doi.org/10.1136/ejhpharm-2024-eahp.372
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 15PSQ-104 Real-world evidence: is ibrutinib as safe as evidence tells?2024 · 1 citations
  2. 2A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)2024 · 1 citations
  3. 3Long‐Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib2026
  4. 46ER-037 Pharmaco-utilisation of ibrutinib in CLL: a single centre study2024 · 1 citations
  5. 5Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre <scp>REALITY</scp> study2024 · 4 citations